Chief Laboratory Operations Officer
Todd Arnold, Ph.D. was the Managing Director of the Mount Sinai Genetic Testing Laboratory in Branford, Connecticut and led the establishment of this state of the art, high throughput nucleic acid sequencing facility. Dr. Arnold has extensive experience in product and assay development, most recently as the Vice President of Research and Development at 454 Life Sciences, a Roche Company. Prior to his tenure at 454 Life Sciences, he led research and development teams at 3M Corporation and Millipore. He is a strong advocate for Connecticut’s bioscience and technology ecosystem, serving on the advisory boards of a number of industry and non-profit organizations. He is also an active participant in STEM curriculum development at colleges and universities in Connecticut and nationwide. Dr. Arnold earned his B.S. in Biological Sciences from Indiana University, his Ph.D. in Molecular Biology and Genetics from the University of Georgia, and was a postdoctoral fellow at Harvard Medical School.
SVP of Bioinformatics R&D
Rong Chen, Ph.D., was the Director of the Clinical Genome Informatics Laboratory, and Assistant Professor in the Department of Genetics and Genomic Sciences and Institute of Genomics and Multiscale Biology at Icahn School of Medicine at Mount Sinai. Dr. Chen is an expert on translational bioinformatics and has published more than 80 papers in journals such as Nature Biotechnology and The Lancet. He has developed numerous databases and software tools to interpret genomes to help drive clinical diagnosis, precision medicine, and therapeutic target discovery, including knowledge bases for various clinical genetic testing, VIAS for genetic variant annotation, ClinLabGeneticist for clinical exome sequencing, and ZDOCK, one of most widely-used protein-protein docking programs. Dr. Chen led the Resilience Project, a study designed to identify genetic ‘superheroes’ in more than 589,000 individuals, and a personalized cancer therapy project for precision medicine. He has illustrated the genetic landscapes of parathyroid carcinoma and Cushing’s disease, identified potential therapeutic targets for cardiovascular diseases, and identified diagnostic biomarkers for organ transplant rejection. Dr. Chen also developed novel methods to predict personal risk of disease by integrating genome sequencing, electronic medical records, and environmental factors. He published the first Clinical Assessment of Human Genome and was a leader in the development of the personal genome report. Before joining Mount Sinai, Dr. Chen built and launched the genomic medicine startup company, Personalis. He has also worked at Accelrys/BIOVIA, Quest Diagnostics Nichols Institute, Abgenix/Amgen, and Stanford University. Dr. Chen received his B.S. in Chemical Physics from the University of Science and Technology in China, his M.S. in Structure Biology from Chinese Academy of Sciences, and his Ph.D. in Bioinformatics from Boston University.
Dan is a mission-driven advocate overseeing all legal and regulatory matters for Sema4. Prior to joining Sema4, Dan practiced with two leading law firms in New York, clerked for Judge Frederic Block in the Eastern District of New York, and helped found a boutique startup law firm. Dan graduated with honors from the University of Michigan School of Law and Pomona College, and he traveled as a Thomas J. Watson Fellow.
President and Chief Operating Officer
James Coffin, Ph.D., also known as Jamie, is a pioneer in the healthcare and life sciences sector. He recently served as Chief Executive Officer and President at Source Medical Solutions, the #1 provider of practice management and EMR solutions in the Ambulatory Surgical space. Previously, Jamie was Worldwide Vice President and General Manager at Dell, leading the Global Healthcare Life Science (HCLS) business over a six-year period to become the #1 healthcare IT services company in the world with $3.5b in revenue, and a workforce of ~13,000 people. He pioneered Dell’s efforts to apply leading-edge information technology into areas including EMR, data analytics, high performance and cloud computing, personalized medicine, claims processing, medical imaging, and pharmaceutical and biotech drug discovery. Prior to Dell, he served as Worldwide Vice President of IBM Healthcare and Life Sciences and grew the division to a $6.5b business. He was also a Director at Terascala Inc.
Chief Medical Officer – Reproductive Health
Alan B. Copperman, M.D. is the Director of the Division of Reproductive Endocrinology and Infertility and the Vice-Chairman of the Department of Obstetrics, Gynecology and Reproductive Science at The Icahn School of Medicine at Mount Sinai. Dr. Copperman was a co-founder and serves as Medical Director of RMA of New York, one of the largest and most prestigious IVF Centers in the country. He is an experienced and respected clinician, and has a long history of achieving success in treating infertility and in applying fertility preservation technologies. He has published numerous manuscripts and book chapters on reproductive medicine, and has co-authored hundreds of scientific abstracts on infertility, in vitro fertilization, egg freezing, ovum donation, and genetics. Dr. Copperman is frequently quoted in print and digital media, including the Associated Press, Wall Street Journal, U.S. News & World Report, The New York Times, WebMD, SELF, Health.com, Parenting magazine, Parents.com, and Refinery29. He has been featured on local and nationally-televised news shows, including Fox 5 NY Live, CBS This Morning, Huffington Post Live, Anderson Cooper 360, and 20/20. Dr. Copperman was named to New York magazine’s list of Best Doctors sixteen years in a row. He has been recognized annually by Castle Connolly and SuperDocs as one of the top fertility doctors and by his peers and patient advocacy organizations for his commitment to patient-focused and data-driven care.
Chief Diagnostics Officer
Lisa Edelmann, Ph.D. was the Executive Director of the Mount Sinai Genetic Testing Laboratory and holds the academic title of Associate Professor in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. Dr. Edelmann received her Ph.D. in Molecular Genetics from The Albert Einstein College of Medicine, and is certified in Clinical Molecular Genetics and Clinical Cytogenetics by the American Board of Medical Genetics and Genomics. Her scientific accomplishments include, elucidating the mechanism of chromosome 22q11 rearrangements and involvement in the first molecular sequencing of an entire human chromosome. She has also published extensively on Ashkenazi Jewish genetic disorders and has developed several novel tests, including a test for detection of silent carriers for spinal muscular atrophy, which is being licensed nationwide and abroad. Dr. Edelmann is a nationally recognized expert in population-based carrier screening, high-throughput clinical diagnostic sequencing as well as genomic disorders and clinical interpretation of copy number variation. She is well versed with the regulatory guidelines that govern clinical laboratories and has extensive experience with the process of validating LDTs and bringing them to market.
Chief Marketing Officer & EVP of R&D
Glenn has over twenty years of experience in developing brand strategy and leading high impact marketing programs to drive growth for companies and organizations in industries ranging from biotech and healthcare to software, big data, and online services. Prior to Sema4, he was Chief Marketing Officer of the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai, where the team is driving precision medicine through data science. Previously, he led brand and marketing communications at Pacific Biosciences, a Silicon Valley biotech offering a genomic analysis platform, where he played an integral role in the company’s successful IPO and helped drive the rapid expansion of the company’s worldwide marketing and sales efforts. Prior to PacBio, Glenn led the brand and marketing strategy team at Microsoft for its flagship Windows products, Server software portfolio, and online services. He led the Microsoft corporate brand team that created Bing for web search, and repositioned Xbox for broader consumer appeal.
Chief Analytics Officer
Krish Ghosh, Ph.D., has over twenty-five years of experience in the pharmaceutical industry, a strategic thinker with experience working with senior executives and consulting firms to develop and execute business strategies in big Pharmaceutical and Contract Research Organization. Prior to joining Sema4, Krish has successfully led cross-functional global teams across sites and regions at LabCorp/Covance for over 13 years, in software development, informatics, big-data analytics, portfolio management, resource management, high-end statistics, and clinical trial optimization. Krish has broad understanding of clinical operations and application of AI tools to derive industry leading capabilities in clinical trial management and conduct. Krish has successfully created the vision and led the development of a few leading differentiators for Covance, to optimize patient recruitment, study design, investigator selection, forecasting, and resource demand/supply management for any global trial, using Covance drug development, LabCorp patient, and RWD/publicly available data. Prior to that, Krish spent over 12 years between Wyeth Pharmaceuticals and Bristol Myers Squibb, where he worked across the entire drug development continuum, including Discovery, Preclinical, Clinical/Regulatory, project planning, portfolio management, resource management and R&D benchmarking. Prior to that, Krish spent 4 years in the Academic environment as Assistant Professor, offered several graduate and undergraduate courses and supervised graduate students. Krish received both his PhD is Statistics and MBA in Finance from Temple University in Philadelphia, PA.
Chief Information Security Officer
Shay brings more than two decades of experience of technical management and leadership skills, helping Sema4 implement its information technology and predictive, personalized healthcare platform, as well as various other clinical systems using cloud-based architecture. Shay has in-depth technical experience with diverse technologies, including cloud computing, in-memory computing, and big data. Shay has been involved with large scale projects in different verticals working with Fortune 500 multinational global companies, including financial services, telecom, healthcare, e-commerce, travel, logistics, homeland security, and more. Prior to joining Sema4, Shay was part of the GigaSpaces XAP and Cloudify product leadership teams from their inception, overseeing the technical activities of the U.S. operations, serving as Deputy CTO Distinguished engineer, and escorting the pre-sale and post-sale activities. Prior to GigaSpaces, Shay served as a Lead Architect and Technical Manager at Versant ODBMS, and VMDB Database Tools Lead Architect at Sirius Technologies. Shay holds a B.Sc. in Electrical and Computer Engineering from Ben-Gurion University in the Negev.
Head of Statistical Genomics
Ke Hao, ScD, Head of Statistical Genomics at Sema4, leads the development of prediction models for complex human diseases by integrating genetic predisposition and environmental / life style factors. Dr. Hao is also an Associate Professor at the Icahn School of Medicine at Mount Sinai in the Department of Genetics and Genomic Sciences and Institute for Data Science and Genomic Technology. His main focus is on discovering genetic and environmental basis of human diseases comprised of leading-edge research in translational statistical genetics, and applying computational algorithms, e.g. polygenic risk score and machine learning approaches, to mine massive datasets and deliver clinical utility and insights.
Dr. Hao was trained in statistical genetics and environment health with a BSc at Tsinghua University, China, and a ScD at Harvard University School of Public Health. Dr. Hao has extensive experiences working in both biotech and pharmaceutical companies (Affymetrix, Inc, and Merck & CO) on high dimensional ‘omics data modeling and product development. He is also funded by grants from NIH and other agencies, and developed novel methods that are widely used in statistical genomics and environment health research. He is one of the pioneers studying the role of genetics and environment exposure during early life, including in utero period, and the health consequences. Dr. Hao developed a hardware/software system, Bio3Air, to long-term measure ambient pollutant exposure at individual level, which has been deployed in multiple human studies. Further, he led the first study demonstrating the influence of air pollution on human respiratory tract microbiome and health outcomes. Dr. Hao has published extensively in the fields of statistical genomics, epidemiology and environmental health, with more than 100 peer-reviewed papers in journals including Science, Nature Genetics, Nature Neuroscience and Nature Communications.
VP, Clinical Informatics
Li Li, M.D., is Vice President of Clinical Informatics at Sema4, leading the development of a common data model for electronic medical records (EMR), driving the development and improvement of clinical applications for reproductive diseases, newborn health, and deep imaging learning and aiming to advance novel diagnostics, therapeutics, and insights into both diseases and wellness.
Also, Dr. Li is an Assistant Professor at the Icahn School of Medicine at Mount Sinai in the Department of Genetics and Genomic Sciences and the Institute for Next Generation of Healthcare.
Dr. Li was trained as both a physician and bioinformatician, with an M.D. in Clinical Medicine from the Dalian Medical School in China and an M.S. in Bioinformatics from Boston University, and has over 16 years of experience in both industry (Quest Diagnostics) and academia (Stanford University, UCSD) with a focus on EMR and multi-omics data. At graduate school, she developed RDOCK, which has become one of the most widely-used protein-protein docking software programs. She successfully established the precision medicine groundwork including deep phenotyping of Lyme Disease, categorizing subtypes of type 2 diabetes for treatment stratification rather than one size fits all model, developing deep machine learning algorithms to improve disease prognostics, identifying key clinical risk factors from EMR to improve quality of care for patients, and developing biomarker diagnostic assays for acute rejection and tolerance of kidney transplantation. She has received four Young Investigator Awards from the American Society of Transplantation and the Transplantation Society. Her three international patents led to the creation of the start-up company Organ-I Inc., acquired by IMMUCOR Inc., and one patent of identification of drug targets to treat kidney fibrosis and chronic graft injury. Dr. Li has published extensively in the fields of precision medicine, bioinformatics, and clinical bioinformatics, with more than 75 peer-reviewed papers in journals including Nature Biotechnology, Science Translational Medicine, and PNAS.
VP, Human Resources
Bobbie Lyons is a seasoned Human Resources professional whose career spans leadership roles in the real estate, public relations, consulting, and entertainment industries. Before joining Sema4, she was the Senior Vice President of Human Resources at Rouse Properties, Inc. where she developed an original human resources function and proceeded to drive all human capital initiatives for the company. Bobbie has a track record of working with start up organizations having installed human resources functions in 3 such companies. She is a past Board Member of the Society for Human Resources Management, and has been an adjunct instructor at Sacred Heart and New York Universities. She is a certified administrator of the Occupational Personality Questionnaire Assessment Instrument (OPQ).
Chief Compliance Officer
At Sema4, Murali is responsible for governance, risk and compliance, and ensuring trust and transparency with patients, regulators, clients, institutional review boards, and business partners. He drives policies and procedures, and internal and external audits to comply with key regulations, standards, and certifications. Prior to joining Sema4 in September 2020, Murali was the Director of Compliance at IBM Watson Health where he built a quality and compliance program for an extensive portfolio of SaaS and on-premises health products and services in more than 10 countries. He also established data governance frameworks and workflows for health data analytics on datasets with more than 300 million patients. Before joining Watson Health, Murali was the Senior Privacy Officer for Philips Group Innovation, with responsibility for overseeing several hundred human subject studies across approximately a dozen countries. Murali has a Ph.D. in Mechanical Engineering from Northwestern University and holds Certified Information Privacy Professional (CIPP) and Project Management Professional (PMP) credentials from the International Association of Privacy Professionals and Project Management Institute, respectively.
SVP, Solutions Sales
Sheila Moran has over two decades of experience building, coaching, and leading high performance, consultative sales teams in the Healthcare Industry. Prior to Sema4 she was VP of Sales for the Therapy division of Source Medical leading the team to double their business in Software and Revenue Cycle Management culminating in the successful sale of the business. She held a variety of leadership positions domestically and globally over a 20 year tenure at IBM where she led teams in complex solution sales to the Healthcare Provider, Payer, and Pharma Industries including Data Mining and Analytics, Clinical Genomics, Research Computing Solutions, and Commercial Production Systems. Sheila has held dual roles in operations, marketing and product development enabling her to bring a deeper level of experience to growing emerging businesses as well as driving new growth in established businesses. Sheila earned a BS in Chemical Engineering from the Illinois Institute of Technology in Chicago.
Chief Commercial Officer
Thomas A. Neyarapally was previously a member of the founding team and Executive Vice President, Corporate Development at the healthcare analytics company GNS Healthcare, where he led the expansion of GNS’ business from systems biology into the commercial groups within pharma as well as payers and providers, and secured the company’s core intellectual property. Tom also helped launch Cibo Technologies, an agriculture predictive modeling startup, as Chief Operating Officer, and served as a corporate and intellectual property lawyer at Chadbourne & Parke LLP and Frommer Lawrence & Haug LLP. He started his career as a pharmaceuticals analyst at the management consulting firm Arthur D. Little. Tom received his degree in chemical engineering, cum laude and as an Honors Scholar, from the University of Connecticut, and JD and MBA degrees from Cornell University.
Chair, Scientific Advisory Board for Oncology
William K. Oh, MD, an expert in the management of genitourinary malignancies, including prostate, renal, bladder, and testicular cancers, is Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute, an NCI-designated cancer center, at the Icahn School of Medicine at Mount Sinai. He is also Professor of Medicine, and Urology, and is the Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics.
Dr. Oh’s research interests include novel biomarkers and therapeutics in advanced prostate cancer. In addition to serving as the Principal Investigator of multiple clinical trials in prostate cancer, he has developed large clinical databases and specimen repositories for genitourinary cancers at both Harvard Medical School and the Dana-Farber Cancer Institute and at Mount Sinai, which have enrolled more than 10,000 patients with prostate, renal, and bladder cancer.
Dr. Oh has authored more than 300 articles, reviews, and book chapters on topics relating to prostate, renal, bladder, and testicular cancers. He has edited three books on prostate cancer. He has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association, including the Guidelines Committee for Advanced Prostate Cancer. In addition to reviewing for top journals such as The New England Journal of Medicine, Journal of Clinical Oncology, and Cancer, Dr. Oh co-edits “Testicular Cancer” for Up to Date and is Associate Editor of CA: A Cancer Journal for Clinicians. He is a member of the prestigious American Society for Clinical Investigation and has been repeatedly selected as a Top Doctor in New York magazine, Castle Connolly, Best Doctors, and Super Doctors over the past decade.
Dr. Oh received his MD from New York University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women’s Hospital in Boston. He then completed a fellowship in medical oncology at the Dana-Farber Cancer Institute in 1997.
Prior to joining Mount Sinai in 2009, Dr. Oh served as Clinical Director of the Lank Center for Genitourinary Oncology and directed the Gelb Center for Translational Research at the Dana-Farber Cancer Institute and Harvard Medical School in Boston. He was also the founding Chair of the Data and Safety Monitoring Committee for Phase I/II Trials at the Dana-Farber/Harvard Cancer Center.
SVP of R&D
Qi Pan, Ph.D., has over 14 years of experience in biotech and pharmaceutical R&D and gained in-depth knowledge on oncology and biotherapeutic drug discovery and development. Prior to Sema4, she was VP of R&D at Legend Biotech, a leading biotech company in the development of BCMA CAR-T therapy to treat multiple myeloma. At Legend Biotech, Qi led a team of scientists to work on innovative CAR-T preclinical research portfolio aiming to cure both hematological and solid tumors, and she was also responsible in setting Legend Biotech’s cancer immunotherapy R&D strategies. Previously, Qi worked in pharmaceutical companies such as Genentech and Boehringer Ingelheim and had led project teams to deliver multiple high quality biotherapeutic molecules from research to clinical development, including cancer indications and auto-immune indications. At Boehringer Ingelheim, Qi was also responsible for leading exploratory biotherapeutic portfolio for Tumor Immunology and Immune Modulation. Qi received her Ph.D. from Harvard University in the field of molecular and cellular biology.
Head of Disease Discovery
As Head of Disease Discovery at Sema4, Lauren Peters, Ph.D. is designing next generation in silico models of disease to uncover patient data driven mechanisms of disease pathogenesis and identification of novel patient subsets, biomarkers and approaches to therapeutic discovery. Dr. Peters is also an Assistant Professor in the Department of Genetics & Genomic Sciences and the Icahn Institute for Data Science & Genomic Technology at the Icahn School of Medicine at Mount Sinai where she has focused on the analysis and experimental validation of computational models of disease in collaboration with Janssen and led numerous publications including in Nature Genetics, Gastroenterology and Nature Immunology. Prior to completing her Ph.D. in Biomedical Science at the Icahn School of Medicine at Mount Sinai in Immunology and Genetics, Dr. Peters was a scientist in oncology therapeutic discovery in the Cell Biology group in R&D at Imclone Systems, Eli Lilly, worked in business development at Regeneron and in Genetics and Development at Columbia University, where she earned a M.A. in Biotechnology. Dr. Peters also has worked in Information Technology at Barclays and management consulting at Kaiser Associates; advising Fortune 100 clients in the pharmaceutical, technology and other industries on business strategy. She holds a BA in International Relations with a concentration in Economics from Boston University.
VP, Business Development
Prior to joining Sema4, Matt was Senior Vice President of Business Development of Surgical Information Systems(SIS) and assisted in transitioning the partner programs he had built prior to the SIS acquisition of SourceMed, a PE-backed healthcare IT and services company focused on practice management, revenue cycle and clinical documentation of outpatient clinics. Through the partner program, Matt drove innovation and positive growth in the legacy SourceMed business that supported the SIS transaction. Prior to SourceMed, Matt led many Business Development activities over 15 years at Dell, Inc. primarily serving the Healthcare and Life Sciences markets in solution creation, partnerships and incubation of net new technologies. Matt is recognized as a subject matter expert in patient and provider engagement and has built, led, and launched many net new businesses to market all focused on delivering better healthcare outcomes. Prior to Dell, Matt owned a small business in the restaurant industry.
Chief Product Officer
Tony Prentice is an innovative product developer, strategist, and leader. Tony was the Vice President of Mobile Payments at American Express, where he built the organization for new commerce products, applications, and mobile wallets. The team delivered enterprise strategy and products including Apple Pay, Android Pay, and the Amex app. Previously he had various product management roles at American Express including Gold Card, Starwood, Hilton and Blue cards. Prior to Amex, Tony had various product, general manager and engineering roles at Starbucks, McKinsey & Co and GE.
Chief Executive Officer
Eric Schadt, Ph.D., is founder and CEO of Sema4, a patient-centered predictive health company built on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Dr. Schadt also serves as the Dean for Precision Medicine and Mount Sinai Professor in Predictive Health and Computational Biology at the Icahn School of Medicine at Mount Sinai. He was previously Founding Director of the Icahn Institute for Genomics and Multiscale Biology, and Professor and Chair of the Department of Genetics and Genomic Sciences. Dr. Schadt is an expert on constructing predictive models of disease that link molecular biology to physiology to enable clinical medicine. Over the past 20 years, he has built groups and companies (Merck, Rosetta, Sage Bionetworks, Pacific Biosciences, Icahn Institute, and now Sema4) to elucidate the complexity of human diseases. He has published more than 350 peer-reviewed papers in leading scientific journals and contributed to discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease. Now, with Centrellis™, Sema4’s innovative health intelligence platform, Dr. Schadt is using advanced network analysis to build better models of human health and deliver personalized insights for patients.
VP of Technology Development
Robert Sebra, Ph.D. will lead Technology Development for Sema4 with technology adoption, and research and development to create high-throughput diagnostics and innovative IP. Dr. Sebra has vast experience in molecular, biochemical, and sequencing technology including surface bioconjugation techniques, lab-on-a-chip platforms, active biomaterials, single-molecule platforms, and the integration of bulk and single cell sequencing technologies for basic science and clinically driven applications. He is a leading expert in sequencing platforms and a pioneer in new approaches for single molecule and single cell assay development. Dr. Sebra has published more than 50 papers in top tier journals, including Science, Cell, Nature, NEJM, and Cancer Discovery, and his work has led to multiple issued patents. Dr. Sebra will continue as the Director of Technology Development at the Icahn Institute of Genomics and Multiscale Biology and an Associate Professor in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai in New York. Since establishing a team at Icahn School of Medicine at Mount Sinai, Dr. Sebra has applied WGS and targeted genomics approach toward a better understanding of genomic variation for higher resolution human disease diagnostics in cancer and inherited disease, alongside infectious disease surveillance using both long- and short-read sequencing techniques. Prior to his work at Sinai, Dr. Sebra was involved in research and development contributing to single molecule real-time long read sequencing technology and applications at Pacific Biosciences after receiving his Ph.D. in Chemical and Biological Engineering at University of Colorado, Boulder.
Chief Financial Officer
Joel has over 30 years of experience as an executive, analyst, and banker in the biotechnology industry. He has worked as an industry executive for over a decade, most recently as Chief Financial Officer of Spero Therapeutics. Prior to that he was CFO of Forward Pharma A/S. He led the successful initial public offerings of both companies. He previously spent over 17 years as a senior equity research analyst covering biotechnology. As an analyst, he served as a Managing Director at Stifel Financial Corp. where he led the firm’s healthcare equity research group, and previously he was a Managing Director at Lazard, where he established the firm’s healthcare equity research effort. Prior to his career in equity research, Mr. Sendek worked as a Senior Director of Corporate Development at Progenics Pharmaceuticals and as an investment banking analyst at Goldman Sachs. Mr. Sendek holds a B.A. in Biochemistry from Rice University.
Chief of Revenue Cycle Services
Tim is an innovative strategist and leader with over 18 years of experience in the healthcare and life sciences sector. He specializes in developing strategy and maximizing payer development & overall company financial performance in healthcare technology startups, IPO’s and publicly traded labs. Tim was previously the VP of Revenue Cycle at Mount Sinai Icahn Institute of Genomics and Multiscale Biology. Prior to joining Mount Sinai, Tim held several senior roles with Kaiser Permanente and Sequenom Labs. During this time he was a pioneer in bringing the development of the first noninvasive prenatal testing (NIPT) to the commercial market. He has successfully developed high impact teams designed for rapid growth & expansion maximizing financial performance in healthcare.
SVP & GM, Women’s Health
Bridget Winders has over 20 years of expertise in business and go-to-market strategy, services and sales in industries ranging from healthcare, education, government, and financial. Prior to Sema4, she was Vice President of the Central and Pacific Northwest region for Dell | EMC and Dell’s Healthcare and Life Sciences organization focused on delivering quality outcomes with data analytics and broad IT solutions. As an early employee of Gateway Computers, Bridget led sales teams through explosive growth amid the company’s evolution from start-up to key player in the burgeoning computer market. In various leadership roles, she has built diverse, multidisciplinary teams that afforded the business effective operations through collaboration.
Head of Data Sciences
Jun Zhu, PhD is a professor in Department of Genetics and Genomic Sciences and a member of Institute of Genomics and Multiscale Biology. Dr. Zhu was trained in both computer science and biomedical science. His research focuses on methodology development for integrating diverse omics data (e.g. genetic, genomic, transcriptomic, proteomic data and etc.) into probabilistic graphic networks. His work has been supported by multiple NIH grants and his methods have been used to identify novel drug targets and elucidate complex human disease mechanisms, which have resulted in publications in top journals in Nature, Nature Genetics, and Cell and multiple patents. Dr. Zhu has extensive experiences working in both biotech and pharmaceutical companies (Amgen, Inc, and Rosetta/Merck & CO, Inc) and academia (Sage Bionetworks, Fred Hutchinson Cancer Research Center, and Icahn School of Medicine at Mount Sinai).
SVP & GM, Oncology Solutions
Michelle is a seasoned healthcare executive with expertise building and growing companies in digital health, health services, health insurance, and health information. Prior to joining Sema4, Michelle served in leadership positions across a number of healthcare growth companies. She served as SVP, US Operations & Business Development for Mavencare, a venture-backed home health company and as Chief Innovation Officer at AlphaCare, a managed care plan acquired by Magellan Health. She was a founding member of Aetna’s commercial innovation team where she built and incubated healthcare start-ups backed by Aetna . Michelle began her career in management consulting with the Boston Consulting Group and in corporate law with Paul Weiss, Rifkind, Wharton & Garrison. Michelle also has experience on the policy side of healthcare and has published on the topic of resource allocation decision making. Michelle holds an Honors Bachelors of Arts in Economics and Criminology, and JD and MBA from the University of Toronto.
SVP, Emerging Business
David Zirl has spent his career designing and implementing go-to-market strategies to help customers take advantage of innovative IT and business solutions that drive changes and transformations in life sciences R&D, healthcare delivery and medical claims processing. He most recently was the Chief Sales Officer for EMSI, a mobile health information collection company. He was an SVP for Xerox Government Healthcare, where his teams delivered Medicaid claims processing and Eligibility services to 10 western states. He previously led solution sales, business development and marketing teams for Dell, IBM, Silicon Graphics and Kendall Square Research. David earned a PhD in ceramic engineering from Rutgers University.